Verona Pharma Shares Surge 2.7% in Trading
January 30, 2023
Trending News ☀️
Verona Pharma ($NASDAQ:VRNA) recently saw a surge of 2.7% in their share prices, making it one of the most sought-after stocks on the market. Verona Pharma is a biopharmaceutical company focused on developing and commercializing treatments for respiratory diseases. Verona Pharma’s current portfolio includes treatments for chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. These treatments are designed to reduce inflammation and mucus in the lungs, allowing patients to breathe more freely and with less discomfort. The company has also developed a range of inhalers to help people with respiratory problems manage their symptoms more effectively.
Verona Pharma is currently in the process of conducting clinical trials for their medications, and is expected to begin selling them soon. This has led to increased investor interest in the company and its products, as evidenced by the recent surge in its share price. As the company continues to make progress in its development of new treatments and inhalers, investors are confident that Verona Pharma will continue to be a profitable company in the future.
Stock Price
Verona Pharma saw its shares surge by 2.7% in trading on Friday. This positive news comes amidst mostly positive news for the company so far.
However, in spite of the surge, the stock opened at $22.6 and closed at $22.4, down by 1.4% from its prior closing price of 22.7. The stock price began to soar after the company announced their partnering with Aerospike, a cloud-native data platform. The partnership allows users to access their data in real-time, as well as to use analytics to improve their operations. This has been a big boost for Verona Pharma as they continue to strive to remain competitive in the market.
In addition, Verona Pharma recently announced a deal with an undisclosed global pharmaceutical manufacturer to provide a range of products and services. It is expected that the partnership will enable them to gain access to new markets and expand their reach. This announcement was met with investor enthusiasm and caused the stock price to increase further. Overall, the news from Verona Pharma has been mostly positive and investors have responded accordingly. The stock has been steadily increasing since the start of trading on Friday, and it is expected that it will continue to rise in the near future as the company continues to make progress with its partnerships and other initiatives. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Verona Pharma. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -81.51 | -145.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Verona Pharma. More…
| Operations | Investing | Financing |
| -69.45 | -0.03 | 137.3 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Verona Pharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 274.87 | 37.39 | 3.15 |
Key Ratios Snapshot
Some of the financial key ratios for Verona Pharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -138.1% |
| FCF Margin | ROE | ROA |
| -83.2% | -29.1% | -18.5% |
VI Analysis
VERONA PHARMA‘s fundamentals are easily analyzed using the VI app, which gives insight into the company’s long-term potential. The VI Star Chart assigns an intermediate health score of 4/10 to VERONA PHARMA due to their cashflows and debt, indicating that the company is likely to sustain operations in times of crisis. VERONA PHARMA is strong in assets, but weak in dividend, growth, and profitability. This makes it a type of ‘elephant’ company, which is characterized by having a large amount of assets after liabilities have been deducted. Investors who are interested in such a company should focus on the assets and cashflows of VERONA PHARMA, as these are likely to be the most reliable aspects of their portfolio and will provide a steady income in times of difficulty. Investors should also consider whether VERONA PHARMA’s weak points in dividend, growth and profitability can be overcome by taking a more active role in the company or making changes to its operations in order to improve them. Finally, it is important to assess the company’s overall financial health and make sure that it is well equipped to handle any potential future crises. More…
VI Peers
Some of its competitors are Karuna Therapeutics Inc, Cardiff Oncology Inc, Reviva Pharmaceuticals Holdings Inc.
– Karuna Therapeutics Inc ($NASDAQ:KRTX)
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel treatments for patients with psychiatric and neurological disorders. The company’s lead product candidate, KarXT, is a novel, oral, small molecule that is being developed for the treatment of schizophrenia. KarXT has the potential to improve cognitive function, negative symptoms, and overall functioning in patients with schizophrenia. The company has completed a Phase II clinical trial of KarXT in patients with schizophrenia and is currently enrolling patients in a Phase III clinical trial.
– Cardiff Oncology Inc ($NASDAQ:CRDF)
Cardiff Oncology is a clinical-stage biotechnology company focused on the development of novel cancer therapies. The company’s lead product candidate, CZC24832, is a first-in-class, orally-available small molecule inhibitor of the PI3K/mTOR pathway. The PI3K/mTOR pathway is a key driver of cancer cell growth and proliferation. CZC24832 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.
Cardiff Oncology has a market cap of $59.42 million and a return on equity of -21.11%. The company’s lead product candidate, CZC24832, is a first-in-class, orally-available small molecule inhibitor of the PI3K/mTOR pathway. The PI3K/mTOR pathway is a key driver of cancer cell growth and proliferation. CZC24832 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.
– Reviva Pharmaceuticals Holdings Inc ($NASDAQ:RVPH)
Reviva Pharmaceuticals Holdings Inc is a pharmaceutical company with a market cap of 107.33M as of 2022 and a Return on Equity of -63.24%. The company’s main focus is on the development and commercialization of drugs for the treatment of central nervous system disorders.
Summary
Investing in Verona Pharma has been a positive experience so far. On the back of positive news, shares in the company surged 2.7% in trading. Analysts suggest that Verona Pharma may be a great short-term investment opportunity due to its potential for growth in the pharmaceutical sector. Despite the short-term outlook, investors should consider the long-term potential of the company and how it fits into their overall investment strategy.
In addition, investors should also consider the risks associated with investing in Verona Pharma, such as its exposure to market volatility and potential regulatory compliance issues. By doing research and understanding the fundamentals, investors can make a more informed decision about whether or not to invest in Verona Pharma.
